Overview

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Status:
Enrolling by invitation

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.

Phase:

Phase 2

Details

Lead Sponsor:

Cerevel Therapeutics, LLC

Treatments:

PF-06372865